Loss of response

When a medicine that was working stops controlling Crohn's.

Also called: secondary loss of response, primary non-response, stopped working, medicine not working, non-responder

Related words anti-drug antibodies therapeutic drug monitoring

Topics Biologics and newer medicines Flare-ups

Questions people ask

Why does my team check drug levels and antibodies on infliximab or adalimumab?

Some people's bodies make antibodies against infliximab or adalimumab, which can stop the medicine working. Crohn's & Colitis UK says your team may check the level of medicine and antibodies in your blood. The 2025 BSG guideline says these tests can help decide whether to adjust treatment or switch to a different medicine, and NHS Lothian describes checking levels after starting and then at least yearly. Taking an immunomodulator alongside can lower the chance of antibodies.

Sources

What benefits can I get if Crohn's stops me working?

GOV.UK explains that new style ESA may be paid if a health condition limits your work and you have paid enough National Insurance, and that Universal Credit can include extra money if you have limited capability for work, assessed through a work capability assessment. Crohn's & Colitis UK has an overview of UK sickness and disability benefits and suggests using a benefits calculator and a local advice service such as Citizens Advice.

Sources

Why might I take azathioprine or methotrexate alongside a biologic?

The 2025 BSG guideline recommends starting infliximab or adalimumab together with a thiopurine to reduce the chance of the body making antibodies against the biologic. Cochrane reviews found infliximab plus azathioprine or mercaptopurine probably works better than a thiopurine alone. Crohn's & Colitis UK also explains that methotrexate can reduce these antibodies.

Sources

What is upadacitinib (Rinvoq) and how is it different from biologics?

Upadacitinib is a tablet that belongs to a group called JAK inhibitors. It blocks proteins inside cells that switch on the immune response, rather than being an antibody given by drip or injection. Trials found it worked better than placebo for moderate to severe Crohn's, and NICE recommends it after a biologic has failed or when anti-TNFs are unsuitable. Shingles was more common in people taking it.

Sources

Is surgery ever a better choice than a biologic?

Sometimes. The LIR!C trial compared keyhole surgery to remove a short diseased section at the end of the small bowel with infliximab, in people for whom standard medicines had not worked. The researchers concluded surgery is a reasonable alternative for this group, and longer follow-up supported this. It depends on where and how extensive your Crohn's is, so it is a discussion to have with your IBD team and surgeon.

Sources

Where to read more

Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (HTG401, formerly DG22)

NICE Guideline Feb 2016 For professionals

NICE guidance on laboratory test kits that measure how much infliximab or adalimumab is in the blood and whether the body has made antibodies against the drug. The guidance was first published as diagnostics guidance 22 and has been moved into NICE's HealthTech programme without changing its content.

Topics Monitoring Biologics and newer medicines

Jargon explained therapeutic drug monitoring drug level anti-drug antibodies ELISA anti-TNF

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

NICE Guideline Jul 2017 For professionals

NICE's appraisal recommending ustekinumab (Stelara) for adults with moderate to severe Crohn's disease when standard treatment or an anti-TNF medicine has not worked, stopped working or cannot be used. It says the choice between biologics should be made with the patient, using the cheapest suitable option.

Topics Biologics and newer medicines Medicines

Jargon explained interleukin inhibitor TNF-alpha inhibitor biological therapy

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

NICE Guideline Aug 2015 For professionals

NICE's appraisal recommending vedolizumab (Entyvio) for adults with moderate to severe Crohn's disease when an anti-TNF medicine has failed, stopped working or is unsuitable. It is given as a planned course and reassessed at 12 months.

Topics Biologics and newer medicines Medicines

Jargon explained anti-TNF TNF-alpha inhibitor patient access scheme moderately to severely active

Biologic medicines and other targeted treatments

Crohn's & Colitis UK Guide Jul 2023 For patients

An overview of biologics and other targeted medicines for Crohn's and Colitis, with a table of each medicine, its brand names and how it works. It explains that biologics are lab-made antibodies given by drip or injection, and covers biosimilars, anti-TNFs, interleukin inhibitors and JAK inhibitors.

Topics Biologics and newer medicines Medicines

Jargon explained biologic biosimilar anti-TNF IL-23 inhibitor JAK inhibitor advanced therapy

Aminosalicylates for induction of remission or response in Crohn's disease

Cochrane Systematic review Jul 2016 Patients and professionals

Mesalazine-type drugs (aminosalicylates) are widely used for ulcerative colitis, but this review found little evidence that they work for active Crohn's. Low and high doses of mesalazine were not clearly better than placebo. Some trials comparing high-dose mesalazine with budesonide gave mixed results.

Topics Medicines

Jargon explained aminosalicylate 5-ASA mesalazine

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

Gastroenterology Study Jan 2007 Patients and professionals

The main trial behind adalimumab (Humira and its biosimilars) for keeping Crohn's under control. People who improved on adalimumab were much more likely to still be in remission at about a year if they kept taking it (36-41%) than if switched to placebo (12%). Taking it weekly worked no better than every other week.

Topics Biologics and newer medicines

Jargon explained maintenance remission CDAI placebo

Interventions for maintenance of surgically induced remission in Crohn's disease: a network meta-analysis

Cochrane Systematic review Sep 2019 Patients and professionals

Compares the medicines used to stop Crohn's returning after an operation. The evidence was not strong enough to say which works best. Cases of pancreatitis and low white blood cell counts were seen with azathioprine-type drugs.

Topics Surgery Medicines

Jargon explained network meta-analysis endoscopic relapse postoperative recurrence

Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)

NICE Guideline Aug 2025 For professionals

NICE's appraisal allowing guselkumab (Tremfya) for adults with moderate to severe Crohn's disease when earlier treatment has not worked or cannot be tolerated and an anti-TNF medicine is not working or unsuitable. It asks clinicians to choose the least expensive of the suitable options, which include guselkumab, risankizumab and vedolizumab.

Topics Biologics and newer medicines Medicines

Jargon explained IL-23 inhibitor TNF-alpha inhibitor conventional treatment

Search everything for "loss of response"